MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology
Complete the form below to unlock access to ALL audio articles.
MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. Additionally, the companies have entered into a separate agreement, which provides Novartis with an exclusive period to negotiate a research and development collaboration and broader licensing rights related to MDRNA's RNAi drug delivery platform. Terms of this separate agreement were not disclosed.
"We are pleased to enter into this agreement with Novartis, a global leader in the field of RNAi-based therapeutics," stated J. Michael French, President and Chief Executive Officer of MDRNA. "MDRNA's DiLA2 technology for siRNA delivery is effective and efficient at silencing gene targets in the liver and jejunum. Further, the in vivo tolerability of the DiLA2 technology is excellent. We have not observed any delivery related adverse effects in the liver as measured by typical serum chemistries or any significant increases in cytokine levels, which are hallmarks of cell damage. We view this license as yet another important validation of our siRNA technologies and we look forward to a strong and growing relationship with Novartis."
